Thomas Catinazzo Sells 4,865 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 4,865 shares of the company's stock in a transaction on Friday, December 27th. The shares were sold at an average price of $4.42, for a total transaction of $21,503.30. Following the completion of the sale, the chief financial officer now owns 299,226 shares of the company's stock, valued at approximately $1,322,578.92. This trade represents a 1.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, October 28th, Thomas Catinazzo sold 6,802 shares of Relay Therapeutics stock. The shares were sold at an average price of $6.06, for a total transaction of $41,220.12.

Relay Therapeutics Stock Down 1.4 %

Shares of NASDAQ RLAY traded down $0.06 during midday trading on Tuesday, hitting $4.12. The company had a trading volume of 1,417,646 shares, compared to its average volume of 1,566,421. The firm has a market capitalization of $689.62 million, a price-to-earnings ratio of -1.58 and a beta of 1.59. Relay Therapeutics, Inc. has a twelve month low of $4.01 and a twelve month high of $12.14. The business has a 50-day simple moving average of $5.04 and a two-hundred day simple moving average of $6.45.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.14. During the same period in the previous year, the business posted ($0.54) EPS. The company's revenue was down 100.0% compared to the same quarter last year. On average, equities analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC acquired a new stake in Relay Therapeutics in the 2nd quarter valued at about $37,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Relay Therapeutics in the third quarter valued at approximately $63,000. Portland Investment Counsel Inc. purchased a new position in shares of Relay Therapeutics during the 3rd quarter worth approximately $71,000. Values First Advisors Inc. purchased a new position in shares of Relay Therapeutics during the 3rd quarter worth approximately $75,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Relay Therapeutics during the 3rd quarter worth approximately $134,000. Hedge funds and other institutional investors own 96.98% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RLAY shares. Stifel Nicolaus reissued a "buy" rating and set a $28.00 price target on shares of Relay Therapeutics in a report on Monday, September 16th. HC Wainwright cut their price target on Relay Therapeutics from $20.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th. Jefferies Financial Group raised Relay Therapeutics from a "hold" rating to a "buy" rating and increased their price target for the stock from $10.60 to $16.00 in a report on Tuesday, September 10th. Bank of America boosted their price objective on shares of Relay Therapeutics from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, September 10th. Finally, Barclays raised their target price on shares of Relay Therapeutics from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 10th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, Relay Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.50.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.